Cambrex Corp

Find Ratings Reports
CBM : NYSE : Health Care
$52.5 | %
Today's Range: 52.15 - 53.4
Avg. Daily Volume: 333200.0
12/09/16 - 4:02 PM ET

Financial Analysis


CAMBREX CORP's gross profit margin for the third quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased. CAMBREX CORP has strong liquidity. Currently, the Quick Ratio is 1.72 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 28.10% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)99.492.98
EBITDA ($mil)26.2923.65
EBIT ($mil)19.8418.02
Net Income ($mil)9.2211.75


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)90.7460.18
Total Assets ($mil)555.06509.68
Total Debt ($mil)0.030.0
Equity ($mil)366.94286.44


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin44.3144.43
EBITDA Margin26.4425.44
Operating Margin19.9619.38
Sales Turnover0.840.8
Return on Assets11.1813.2
Return on Equity18.2223.72
Debt Q3 FY16 Q3 FY15
Current Ratio3.662.0
Debt/Capital0.00.09
Interest Expense0.00.52
Interest Coverage0.034.85


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)32.1531.53
Div / share0.00.0
EPS0.420.36
Book value / share11.419.08
Institutional Own % n/a n/a
Avg Daily Volume333916.0402932.0

Valuation


BUY. The current P/E ratio indicates a significant discount compared to an average of 34.98 for the Life Sciences Tools & Services industry and a value on par with the S&P 500 average of 25.22. For additional comparison, its price-to-book ratio of 4.44 indicates a significant premium versus the S&P 500 average of 2.79 and a discount versus the industry average of 5.05. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, CAMBREX CORP proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CBM 24.98 Peers 34.98   CBM 14.21 Peers 20.29

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

CBM is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CBM is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CBM 17.42 Peers 24.26   CBM 0.55 Peers 1.39

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

CBM is trading at a discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

CBM trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CBM 4.44 Peers 5.05   CBM -3.80 Peers 48.28

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CBM is trading at a discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CBM is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CBM 3.48 Peers 35.48   CBM 15.37 Peers 13.22

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CBM is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

CBM has a sales growth rate that exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades